Royalty Pharma (NASDAQ:RPRX) Posts Earnings Results

Royalty Pharma (NASDAQ:RPRX) posted its earnings results on Wednesday. The biopharmaceutical company reported $0.04 earnings per share for the quarter, missing analysts’ consensus estimates of $1.27 by ($1.23), FiscalAI reports. The firm had revenue of $674.14 million for the quarter, compared to analysts’ expectations of $758.93 million. Royalty Pharma had a return on equity of 29.25% and a net margin of 33.88%.

Here are the key takeaways from Royalty Pharma’s conference call:

• Royalty receipts grew 14% year over year in the second quarter, while portfolio receipts increased 6% to $773 million and portfolio cash flow reached $736 million, reflecting approximately 95% cash conversion.
• Royalty Pharma raised its 2026 guidance for the second consecutive quarter, now forecasting portfolio receipts of $3.4 billion to $3.5 billion and royalty-receipt growth of approximately 7% to 10%, despite expected headwinds from PROMACTA, TYSABRI biosimilars and the IRA.
• The company acquired a royalty on AstraZeneca’s cliramitug for up to $425 million, gaining a 3.75% worldwide sales royalty on a potential first-in-class treatment for transthyretin amyloid cardiomyopathy with projected peak royalties of approximately $110 million to $190 million.
• Royalty Pharma cited continued progress across its pipeline, including regulatory submissions and approvals, with 19 development-stage therapies and approximately $2 billion of potential peak royalties in the late-stage pipeline; key trial readouts are expected through 2027.
• The company ended June with $812 million in cash, $9.2 billion of investment-grade debt and leverage of 2.8 times adjusted EBITDA, while maintaining more than $4 billion of financial flexibility and returning approximately $367 million to shareholders in the first half.

Royalty Pharma Stock Up 0.5%

Royalty Pharma stock traded up $0.27 during trading hours on Wednesday, hitting $57.75. The stock had a trading volume of 3,536,445 shares, compared to its average volume of 2,750,280. The company has a quick ratio of 2.66, a current ratio of 2.66 and a debt-to-equity ratio of 0.86. The stock has a market capitalization of $33.25 billion, a P/E ratio of 39.29, a price-to-earnings-growth ratio of 10.18 and a beta of 0.43. Royalty Pharma has a 12-month low of $34.08 and a 12-month high of $60.44. The stock’s 50-day moving average price is $56.39 and its 200-day moving average price is $50.30.

Royalty Pharma Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, September 10th. Shareholders of record on Friday, August 14th will be issued a $0.235 dividend. The ex-dividend date of this dividend is Friday, August 14th. This represents a $0.94 annualized dividend and a yield of 1.6%. Royalty Pharma’s payout ratio is 63.95%.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on the company. Morgan Stanley lifted their price target on Royalty Pharma from $61.00 to $63.00 and gave the company an “overweight” rating in a research report on Friday, April 10th. Bank of America reissued a “buy” rating on shares of Royalty Pharma in a research report on Wednesday. Wall Street Zen upgraded shares of Royalty Pharma from a “buy” rating to a “strong-buy” rating in a report on Saturday, May 9th. JPMorgan Chase & Co. upped their target price on shares of Royalty Pharma from $50.00 to $58.00 and gave the stock an “overweight” rating in a research report on Thursday, May 7th. Finally, TD Cowen upped their target price on shares of Royalty Pharma from $50.00 to $65.00 and gave the stock a “buy” rating in a research report on Monday, July 13th. Eight investment analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of $56.57.

More Royalty Pharma News

Here are the key news stories impacting Royalty Pharma this week:

• Positive Sentiment: Royalty receipts and guidance increased. Portfolio Receipts rose 6% to $773 million, while Royalty Receipts grew 14%. Management raised its 2026 Portfolio Receipts outlook to $3.4 billion-$3.5 billion, signaling confidence in the underlying royalty portfolio. Royalty Pharma reports second quarter 2026 results
• Positive Sentiment: Cash generation remained strong. Net cash provided by operating activities reached $728 million, supporting Royalty Pharma’s ability to fund acquisitions, dividends and other shareholder returns. Adjusted earnings of $1.32 per share also exceeded the $1.27 consensus estimate and increased from $1.14 a year earlier. Royalty Pharma Q2 earnings report
• Neutral Sentiment: Reported results contain a measure-related discrepancy. MarketBeat cited GAAP EPS of $0.04 and revenue of $674.1 million, below consensus revenue of $758.9 million, while Zacks highlighted adjusted EPS of $1.32 and described revenue as beating estimates. Investors are likely emphasizing royalty receipts and adjusted earnings, but the difference between GAAP and adjusted results may add volatility. Royalty Pharma earnings report
• Negative Sentiment: Valuation and target-price risks remain. Royalty Pharma trades near the upper end of its 52-week range, while one brokerage consensus target of $56.57 is below the recent trading level. That could limit near-term upside unless the raised guidance translates into further analyst upgrades. Royalty Pharma target price coverage

Insider Activity

In related news, EVP Marshall Urist sold 9,099 shares of the business’s stock in a transaction that occurred on Wednesday, July 1st. The shares were sold at an average price of $55.88, for a total value of $508,452.12. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Terrance P. Coyne sold 64,399 shares of the business’s stock in a transaction that occurred on Tuesday, May 26th. The stock was sold at an average price of $53.98, for a total transaction of $3,476,258.02. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 393,009 shares of company stock worth $21,601,827. Corporate insiders own 18.84% of the company’s stock.

Institutional Trading of Royalty Pharma

A number of institutional investors and hedge funds have recently modified their holdings of RPRX. CIBC Private Wealth Group LLC raised its stake in shares of Royalty Pharma by 66.4% in the fourth quarter. CIBC Private Wealth Group LLC now owns 1,118 shares of the biopharmaceutical company’s stock worth $43,000 after purchasing an additional 446 shares during the last quarter. Larson Financial Group LLC boosted its position in shares of Royalty Pharma by 31.9% during the third quarter. Larson Financial Group LLC now owns 1,264 shares of the biopharmaceutical company’s stock valued at $45,000 after buying an additional 306 shares during the last quarter. Smartleaf Asset Management LLC boosted its position in shares of Royalty Pharma by 59.5% during the fourth quarter. Smartleaf Asset Management LLC now owns 1,405 shares of the biopharmaceutical company’s stock valued at $55,000 after buying an additional 524 shares during the last quarter. Transamerica Financial Advisors LLC increased its holdings in Royalty Pharma by 10.7% in the 4th quarter. Transamerica Financial Advisors LLC now owns 5,158 shares of the biopharmaceutical company’s stock worth $199,000 after buying an additional 498 shares in the last quarter. Finally, Quadrature Capital Ltd bought a new stake in Royalty Pharma in the 4th quarter worth about $205,000. Institutional investors own 54.35% of the company’s stock.

About Royalty Pharma

Royalty Pharma plc is a specialty finance company that acquires biopharmaceutical royalty interests and provides non-dilutive financing to drug developers and rights holders. The firm purchases future royalty streams, milestone-contingent payments and other revenue rights linked to approved and late-stage pharmaceutical and biotechnology products. By paying upfront consideration for these rights, Royalty Pharma seeks to generate long-term cash flows tied to the commercial performance of a diversified portfolio of medicines.

The company’s transaction structures include outright royalty purchases, structured financings and milestone arrangements tailored to the needs of innovator companies, academic institutions and investors.